National, August 19, 2026: Symbiotec Pharmalab Limited has announced that its ₹1,757 crore Initial Public Offering (IPO) will open for subscription on August 24, 2026, and close on August 27, 2026. The anchor investor bidding will take place on August 21.
The price band has been fixed at ₹938 to ₹988 per equity share with a face value of ₹2. Investors can bid for a minimum of 15 shares and in multiples of 15 thereafter. Eligible employees will receive a ₹90 per-share discount under the employee reservation portion.
The IPO comprises a fresh issue of ₹150 crore and an Offer for Sale (OFS) of up to ₹1,607 crore by existing shareholders. The OFS includes shares worth up to ₹144 crore from Satwani Holdings LLP, ₹988 crore from Rosewood Investments and ₹475 crore from India Business Excellence Fund–III.
Symbiotec Pharmalab plans to use the net proceeds from the fresh issue primarily for prepayment or repayment of certain outstanding borrowings, along with general corporate purposes.
The equity shares are proposed to be listed on the BSE and NSE, with BSE serving as the designated stock exchange.
JM Financial, Avendus Capital, Motilal Oswal Investment Advisors and Nomura Financial Advisory and Securities (India) are the book running lead managers for the IPO.
The issue will be conducted through the book-building process in accordance with applicable SEBI regulations.
